Endoscopic Eradication Therapy for Barrett's Neoplasia: Where Do We Stand a Decade Later?
PURPOSE OF REVIEW
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer associated with increasing incidence and poor survival. Early identification and effective treatment of BE-related neoplasia prior to the development of invasive adenocarcinoma are essential to limiting the morbidity and mortality associated with this cancer. In this review, we summarized the recent evidence guiding endoscopic eradication therapies (EET) for neoplastic BE.


RECENT FINDINGS
New sampling technologies and the application of artificial intelligence (AI) systems have potential to revolutionize early neoplasia detection in BE. EET for BE are safe and effective in achieving complete eradication of intestinal metaplasia (CE-IM) and reducing the progression to EAC, a practice endorsed by all GI society guidelines. EET should be considered in patients with high-grade dysplasia (HGD), intramucosal carcinoma (IMC), and select cases with low-grade dysplasia (LGD). The increasing use of endoscopic submucosal dissection (ESD) in the West may allow EET of select cases with submucosal EAC. Post-EET surveillance strategies will continue to evolve as knowledge of specific risk factors and long-term neoplasia recurrence rates improve. In the last decade, major advancements in EET for neoplastic BE have been achieved. These now represent the standard of care in the management of BE-related dysplasia and intramucosal cancer.
['Jones|Blake|B|', 'Wani|Sachin|S|']
D000230:Adenocarcinoma D001185:Artificial Intelligence D001471:Barrett Esophagus D017115:Catheter Ablation D018450:Disease Progression D004938:Esophageal Neoplasms D004945:Esophagoscopy D006801:Humans
Neoplasia Ablation Barrett’s esophagus Endoscopic therapy Esophageal cancer Resection